Filtered By:
Drug: Eloxatin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 66 results found since Jan 2013.

In vitro siRNA-mediated GPX4 and AKT1 silencing in oxaliplatin resistance cancer cells induces ferroptosis and apoptosis
AbstractOxaliplatin is a member of platinum-based chemotherapy drugs frequently used in colorectal cancer (CRC). However, resistance to oxaliplatin causes tumor progression and metastasis.Akt1 andGpx4 are essential regulator genes of apoptosis and ferroptosis pathways. Inhibition of these genes might eradicate oxaliplatin resistance in resistant CRC cells. We compared two cell death strategies to reverse drug resistance in Caco-2 and HT-29 oxaliplatin-resistant cell lines. We used theAKT1-specific siRNA to induce apoptosis. Also,GPX4-specific siRNA and FIN56 were utilized to generate ferroptosis. The effect of these treatm...
Source: Medical Oncology - August 26, 2023 Category: Cancer & Oncology Source Type: research

siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.
Authors: Montazami N, Kheir Andish M, Majidi J, Yousefi M, Yousefi B, Mohamadnejad L, Shanebandi D, Estiar MA, Khaze V, Mansoori B, Baghbani E, Baradaran B Abstract One of the most challenging aspects of colon cancer therapy is rapid acquisition of multidrug resistant phenotype. The multidrug resistance gene 1 (MDR1) product, p—glycoprotein (P—gp), pump out a variety of anticancer agents from the cell, giving rise to a general drug resistance against chemotherapeutic agents. The aim of this study was to investigate the effect of a specific MDR1 small interference RNA (siRNA) on sensitivity of ox...
Source: Cellular and Molecular Biology - December 2, 2015 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

siRNA-E6 sensitizes HPV-16-related cervical cancer through Oxaliplatin: an in vitro study on anti-cancer combination therapy
ConclusionInhibition of E6 oncogene expression and subsequent E6-siRNA with Oxaliplatin combination therapy could be a novel strategy for cervical cancer treatment.Graphical Abstract
Source: European Journal of Medical Research - January 21, 2023 Category: Research Source Type: research

siRNA-induced CD44 knockdown suppresses the proliferation and invasion of colorectal cancer stem cells through inhibiting epithelial-mesenchymal transition
J Cell Mol Med. 2022 Mar 1. doi: 10.1111/jcmm.17221. Online ahead of print.ABSTRACTCD44 has shown prognostic values and promising therapeutic potential in multiple human cancers; however, the effects of CD44 silencing on biological behaviors of cancer stem cells (CSCs) have not been fully understood in colorectal cancer. To examine the contribution of siRNA-induced knockdown of CD44 to the biological features of colorectal CSCs, colorectal CSCs HCT116-CSCs were generated, and CD44 was knocked down in HCT116-CSCs using siRNA. The proliferation, migration and invasion of HCT116-CSCs were measured, and apoptosis and cell-cycl...
Source: J Cell Mol Med - March 1, 2022 Category: Molecular Biology Authors: Weiyan Zou Yi Zhang Guangfu Bai Jialu Zhuang Lin Wei Zishu Wang Meiqun Sun Junbin Wang Source Type: research

Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer
Chemotherapy resistance represents a formidable obstacle in advanced or metastatic colorectal cancer (CRC) patients. It is reported that ATPase copper transporting alpha (ATP7A) plays an important role in chemotherapy resistance in CRC. Here, we identified ATP7A as a potentially key gene of OXA resistance in CRC. The patients with higher expression of ATP7A tended to have platinum drug resistance. While the lower expression of ATP7A by siRNA knockdown resulted in enhancement of OXA sensitivity and increased OXA-induced apoptosis. Further, we demonstrated a novel and safe strategy to increase CRC chemosensitivity by deliver...
Source: Frontiers in Oncology - February 21, 2022 Category: Cancer & Oncology Source Type: research

Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer
This study uncovered the critical role of ASPN in causing OXA resistance in CRC patients and suggests a promising nanoformulation that may be more effective than current standard-of-care medications.PMID:36228517 | DOI:10.1016/j.biomaterials.2022.121827
Source: Biomaterials - October 13, 2022 Category: Materials Science Authors: Cheng-Zhi Huang Yue Zhou Qi-Song Tong Qi-Jia Duan Qing Zhang Jin-Zhi Du Xue-Qing Yao Source Type: research

Silencing the livin gene enhances the cytotoxic effects of anticancer drugs on colon cancer cells.
CONCLUSION: siRNA-mediated down-regulation of livin gene expression could significantly suppress colon cancer growth and enhance the cytotoxic effects of anticancer drugs such as 5-FU and L-OHP. The results of this study suggest that silencing livin gene expression in combination with treatment with anticancer drugs might be a novel cancer therapy for colorectal cancer. PMID: 27904848 [PubMed - in process]
Source: Annals of Surgical Treatment and Research - December 3, 2016 Category: Surgery Tags: Ann Surg Treat Res Source Type: research

Abstract 5382: A breakthrough in application of a drug delivery nanoparticle system for therapy and diagnosis of solid tumor
Conclusion: Our data suggest that sCA itself, while designed as an in vivo delivery device, can facilitate entrance of low molecular chemicals into tumor cells in vitro and in vivo. Citation Format: Xin Wu, Hirofumi Yamamoto, Mamoru Uemura, Taishi Hata, Junichi Nishimura, Ichiro Takemasa, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori. A breakthrough in application of a drug delivery nanoparticle system for therapy and diagnosis of solid tumor. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Wu, X., Yamamoto, H., Uemura, M., Hata, T., Nishimura, J., Takemasa, I., Mizushima, T., Doki, Y., Mori, M. Tags: Cancer Chemistry Source Type: research

Enhancement of Drug Sensitivity by Knockdown of HIF-1α in Gastric Carcinoma Cells.
In this study, the effects of hypoxia-inducible factor-1α (HIF-1α) on gastric carcinoma (GC) drug resistance through apoptosis-related genes are investigated. First, HIF-1α-specific siRNA was synthetized and transfected into drug-resistant GC cell line OCUM-2MD3/L-OHP. Then MTT assay was applied to test the inhibition rate of GC cells by 5-fluorouracil (5-FU) and oxaliplatin (L-OHP). After that, flow cytometry (FCM) was applied to measure apoptosis rate. qPCR and Western blot assay were employed to detect HIF-1α and apoptosis-related genes. Results showed that HIF-1α in OCUM-2MD3/L-OHP cells was higher than that in OC...
Source: Oncology Research - March 6, 2016 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

Cancers, Vol. 11, Pages 1330: Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells
In conclusion, oxaliplatin is a substrate of MRP2 with possibly two binding sites, and silencing MRP2 increased oxaliplatin accumulation and cytotoxicity in two widely available gastrointestinal tumour lines (PANC-1 and Caco-2).
Source: Cancers - September 7, 2019 Category: Cancer & Oncology Authors: Riya Biswas Piyush Bugde Ji He Fabrice Merien Jun Lu Dong-Xu Liu Khine Myint Johnson Liu Mark McKeage Yan Li Tags: Article Source Type: research

The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy.
This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The results demonstrated that th...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 13, 2021 Category: Drugs & Pharmacology Authors: Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Hemmat N, Derakhshani A, Brunetti O, Safaei S, Aghajani M, Najafi S, Silvestris N, Baradaran B Tags: Biomed Pharmacother Source Type: research